Compare Dow Inc (DOW) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs DexCom, Inc. — how do they compare? Dow Inc trades at $28.5 (market cap $20.65B), while DexCom, Inc. trades at $84.38 (market cap $31.86B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and DexCom, Inc. for 62 Days on average.
| DOW | DXCM | |
|---|---|---|
Market Cap | $20.65B | $31.86B |
Volume | 14,126,943 | 3,607,070 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $92.34 |
52-Week Low | $20.65 | $54.84 |
Typical Hold Time | 82 Days | 62 Days |
Enterprise Value | $36.34B | $31.32B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company faces fundamental challenges with negative net income margin (-3.13%) and ROE (-7.86%) despite beating recent EPS estimates. Revenue declined from $56.9B in 2022 to $40.0B in 2025, though 2026 projections show modest recovery to $41.3B. Analyst consensus is mixed with 28% buy ratings but a $34.22 price target suggesting 23% upside potential from current levels.
DOW presents a high-risk opportunity with significant valuation disconnect. While technicals are bearish and profitability metrics weak, the stock trades at attractive valuation multiples (P/S: 0.5x, P/B: 1.3x) with dividend support. Key risks include ongoing margin pressure, declining operating cash flow trend, and rising debt-to-asset ratio approaching 30%. The investment case hinges on earnings recovery and operational turnaround execution.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
